AMENDMENTS TO THE CLAIMS

1. **(Currently Amended)** A process of preparing cells for cell therapy, comprising the steps of:

inducing helper T cells that have a nonspecific antitumor activity; and

imparting antigen specificity to the helper T cells

wherein the step of imparting antigen specificity to the helper T cells comprises ~~is carried out by~~ transducing the helper T cells with a T cell receptor gene that recognizes a cancer-associated antigen.

2. **(Cancelled)**

3. **(Currently Amended)** The process for preparing cells for cell therapy according to claim 1, wherein the T cell receptor gene that recognizes a cancer-associated antigen is ~~step of imparting antigen specificity to the helper T cells is carried out by transducing~~ a MHC class I-restricted T cell receptor gene ~~that recognizes a cancer-associated antigen~~.

4. **(Currently Amended)** The process for preparing cells for cell therapy according to claim 1, wherein the T cell receptor gene that recognizes a cancer-associated antigen is ~~step of imparting antigen specificity to the helper T cells is carried out by transducing~~ a MHC class II-restricted T cell receptor gene ~~that recognizes a cancer-associated antigen~~.

5. **(Previously Presented)** The process for preparing cells for cell therapy according to any of claims 1, 3 or 4, wherein the cancer-associated antigen is selected from the group consisting of Wilms' Tumor 1, CEA, AFP, CA19-9, CA125, PSA, CA72-4, SCC, MK-1, MUC-1, p53, HER2, G250, gp-100, MAGE, BAGE, SART, MART, MYCN, BCR-ABL, TRP, LAGE, GAGE, and NY-ESO1.

6. **(Withdrawn)** The process for preparing cells for cell therapy according to claim 1, wherein the step of inducing helper T cells having a nonspecific antitumor activity is carried out by culturing a T cell-containing material in the presence of anti-CD3 antibody and IL-2.

7. **(Previously Presented)** The process for preparing cells for cell therapy according to any of claims 1, 3, 4 or 6, further comprising a step of purifying the helper T cells to which antigen specificity has been imparted.

8. **(Previously Presented)** The process for preparing cells for cell therapy according to claim 7, wherein the step of purifying the helper T cells to which antigen specificity has been imparted is carried out by using antibody-bearing magnetic beads.

9. **(Currently Amended)** A process of preparing cells for cell therapy, comprising the steps of:

inducing helper T 1 cells and cytotoxic T 1 cells that have a nonspecific antitumor activity; and

imparting antigen specificity to the helper T 1 cells and cytotoxic T 1 cells wherein the step of imparting antigen specificity to the helper T 1 cells and cytotoxic T 1 cells comprises ~~is carried out by~~ transducing the helper T 1 cells and the cytotoxic T 1 cells with a T cell receptor gene that recognizes a cancer-associated antigen.

10. **(Cancelled)**

11. **(Currently Amended)** The process for preparing cells for cell therapy according to claim 9, wherein the T cell receptor gene that recognizes a cancer-associated antigen is ~~step of imparting antigen specificity to the helper T 1 cells and cytotoxic T 1 cells is carried out by transducing~~ a MHC class I-restricted T cell receptor gene ~~that recognizes a cancer-associated antigen~~.

12. **(Currently Amended)** The process for preparing cells for cell therapy according to claim 9, wherein the T cell receptor gene that recognizes a cancer-associated antigen is ~~step of imparting antigen specificity to the helper T 1 cells and cytotoxic T 1 cells is carried out by transducing~~ a MHC class II-restricted T cell receptor gene ~~that recognizes a cancer-associated antigen~~.

13. **(Previously Presented)** The process for preparing cells for cell therapy according to any of claims 9, 11 or 12, wherein the cancer-associated antigen is selected from the group consisting of Wilms' Tumor 1, CEA, AFP, CA19-9, CA125, PSA, CA72-4, SCC, MK-1, MUC-1, p53, HER2, G250, gp-100, MAGE, BAGE, SART, MART, MYCN, BCR-ABL, TRP, LAGE, GAGE, and NY-ESO1.

14. **(Withdrawn)** The process for preparing cells for cell therapy according to claim 9, wherein the step of inducing helper T 1 cells and cytotoxic T 1 cells having a nonspecific antitumor activity is carried out by culturing a T cell-containing material in the presence of anti-CD3 antibody, IL-2, and IL-12.

15. **(Previously Presented)** The process for preparing cells for cell therapy according to any of claims 9, 11, 12 or 14, further comprising a step of separating the helper T 1 cells and cytotoxic T 1 cells to which antigen specificity has been imparted.

16. **(Previously Presented)** The process for preparing cells for cell therapy according to claim 15, wherein the process of separating the helper T 1 cells and cytotoxic T 1 cells to which antigen specificity has been imparted is carried out by using antibody-bearing magnetic beads.

17. **(Previously Presented)** The process for preparing cells for cell therapy according to claim 15, further comprising a step of mixing the separated helper T 1 cells and cytotoxic T 1 cells in any given proportion.

18. **(Withdrawn-Currently Amended)** Cells for cell therapy, that are produced by a process comprising the steps of:

inducing helper T cells that have a nonspecific antitumor activity; and

imparting antigen specificity to the helper T cells, wherein the step of imparting antigen specificity to the helper T cells comprises ~~is carried out by~~ transducing the helper T cells with a T cell receptor gene that recognizes a cancer-associated antigen.

19. **(Withdrawn-Currently Amended)** Cells for cell therapy, that are produced by a process comprising the steps of:

inducing helper T 1 cells and cytotoxic T 1 cells that have a nonspecific antitumor activity; and

imparting antigen specificity to the helper T 1 cells and cytotoxic T 1 cells, wherein the step of imparting antigen specificity to the helper T 1 cells and cytotoxic T 1 cells comprises ~~is carried out by~~ transducing the helper T 1 cells and the cytotoxic T 1 cells with a T cell receptor gene that recognizes a cancer-associated antigen.

20. **(Withdrawn, Currently Amended)** A method for preventing or treating tumor, comprising the steps of:

isolating leukocytes from a patient;

inducing from the leukocytes helper T cells that have a nonspecific antitumor activity;

imparting antigen specificity to the helper T cells, wherein the step of imparting antigen specificity to the helper T cells comprises ~~is carried out by~~ transducing the helper T cells with a T cell receptor gene that recognizes a cancer-associated antigen; and

administering to the patient the helper T cells to which antigen specificity has been imparted.

21. **(Withdrawn-Currently Amended)** A method for preventing or treating tumor, comprising the steps of:

isolating leukocytes from a patient;

inducing from the leukocytes helper T 1 cells and cytotoxic T 1 cells that have a nonspecific antitumor activity;

imparting antigen specificity to the helper T 1 cells and cytotoxic T 1 cells, wherein the step of imparting antigen specificity to the helper T 1 cells and cytotoxic T 1 cells comprises ~~is carried out by~~ transducing the helper T 1 cells and the cytotoxic T 1 cells with a T cell receptor gene that recognizes a cancer-associated antigen; and

administering to the patient the helper T 1 cells and cytotoxic T 1 cells to which antigen specificity has been imparted.

22. (New) The method of claim 1, wherein the T cell receptor gene is isolated from a tumor specific human cytotoxic T cell clone.